Respiratory medicine · 2025
Real-world effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in cystic fibrosis patients with Phe508del -gating and -residual function genotypes.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Salvatore Donatello, Iacotucci Paola, Pepe Angela, Terminiello Alberto, Majo Fabio, Carnovale Vincenzo, Vitullo Pamela, Messore Barbara, Parisi Giuseppe Fabio, Calderazzo Maria Adelaide, Leonetti Giuseppina, Terlizzi Vito
Аннотация
BACKGROUND: Cystic fibrosis (CF) is a genetic disease caused by CFTR protein dysfunction. Elexacaftor/tezacaftor/ivacaftor (ETI) shows promise in improving outcomes for people with CF (pwCF) with Phe508del combined with gating (F/G) or residual function (F/RF) mutations, though real-world evidence remains scarce.
OBJECTIVES: This study evaluated the effectiveness and safety of ETI therapy in pwCF with F/G and F/RF genotypes in real-world settings.
METHODS: A multicentre, retrospective study enrolled 78 pwCF (24 F/G and 54 F/RF) receiving ETI after prior CFTR modulator treatments (ivacaftor and tezacaftor/ivacaftor). Endpoints included changes in ppFEV1, sweat chloride concentration (SCC), CFQ-R respiratory domain scores, body mass index (BMI), pulmonary exacerbations (PEx), and antibiotic use over 24 weeks. Safety was assessed via self-reported adverse events.
RESULTS: ETI improved ppFEV1 (mean increase: 3.8; 95 % CI, 1.8-5.8), SCC (mean decrease: -23.7 mmol/L; 95 % CI, -28.6 to -18.9), and CFQ-R scores (median improvement: 9.4 points; p < 0.05). BMI increased (mean change: 0.41 kg/m2; 95 % CI, 0.05-0.76), while PEx and antibiotic use decreased by 65.2 % and >50 %, respectively (p < 0.001). Subgroup analysis revealed greater ppFEV1 improvement in F/G patients (6.0 points; 95 % CI, 2.6-9.4) compared to F/RF patients (2.8 points; 95 % CI, 0.4-5.2). No serious adverse events were reported.
CONCLUSIONS: ETI therapy provides significant clinical benefits in pwCF with F/G and F/RF genotypes, including improved lung function, SCC normalization, and reduced PEx, compared with previous modulator treatments. Further research is needed to confirm long-term outcomes.
OBJECTIVES: This study evaluated the effectiveness and safety of ETI therapy in pwCF with F/G and F/RF genotypes in real-world settings.
METHODS: A multicentre, retrospective study enrolled 78 pwCF (24 F/G and 54 F/RF) receiving ETI after prior CFTR modulator treatments (ivacaftor and tezacaftor/ivacaftor). Endpoints included changes in ppFEV1, sweat chloride concentration (SCC), CFQ-R respiratory domain scores, body mass index (BMI), pulmonary exacerbations (PEx), and antibiotic use over 24 weeks. Safety was assessed via self-reported adverse events.
RESULTS: ETI improved ppFEV1 (mean increase: 3.8; 95 % CI, 1.8-5.8), SCC (mean decrease: -23.7 mmol/L; 95 % CI, -28.6 to -18.9), and CFQ-R scores (median improvement: 9.4 points; p < 0.05). BMI increased (mean change: 0.41 kg/m2; 95 % CI, 0.05-0.76), while PEx and antibiotic use decreased by 65.2 % and >50 %, respectively (p < 0.001). Subgroup analysis revealed greater ppFEV1 improvement in F/G patients (6.0 points; 95 % CI, 2.6-9.4) compared to F/RF patients (2.8 points; 95 % CI, 0.4-5.2). No serious adverse events were reported.
CONCLUSIONS: ETI therapy provides significant clinical benefits in pwCF with F/G and F/RF genotypes, including improved lung function, SCC normalization, and reduced PEx, compared with previous modulator treatments. Further research is needed to confirm long-term outcomes.